NEVRO CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.88 USD | -3.04% |
|
-14.31% | -54.09% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 440M | Sales 2025 * | 464M | Capitalization | 363M |
|---|---|---|---|---|---|
| Net income 2024 * | -84M | Net income 2025 * | -77M | EV / Sales 2024 * | 0.62 x |
| Net cash position 2024 * | 92.26M | Net cash position 2025 * | 81.38M | EV / Sales 2025 * | 0.61 x |
| P/E ratio 2024 * |
-4.27
x | P/E ratio 2025 * |
-4.71
x | Employees | 1,215 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nevro Corp.
More recommendations
More press releases
| 1 day | -3.04% | ||
| 1 week | -14.31% | ||
| Current month | -6.62% | ||
| 1 month | -25.32% | ||
| 3 months | -41.78% | ||
| 6 months | -41.68% | ||
| Current year | -54.09% |
1 week
9.76
10.78
1 month
9.7613.30
Current year
9.7621.74
1 year
9.7628.47
3 years
9.76182.45
5 years
9.76188.14
10 years
9.76188.14
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Thornal
CEO | Chief Executive Officer | 50 | 23-04-23 |
D. Grossman
CHM | Chairman | 63 | 19-03-18 |
Roderick MacLeod
DFI | Director of Finance/CFO | 57 | 20-06-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael DeMane
BRD | Director/Board Member | 67 | 11-03-16 |
Karen Prange
BRD | Director/Board Member | 60 | 19-12-16 |
D. Grossman
CHM | Chairman | 63 | 19-03-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.10% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 9.88 | -3.04% | 487,090 |
| 24-05-13 | 10.19 | +4.09% | 630,592 |
| 24-05-10 | 9.79 | -6.85% | 675,287 |
| 24-05-09 | 10.51 | +3.44% | 586,707 |
| 24-05-08 | 10.16 | -11.88% | 1,110,814 |
Delayed Quote Nyse, May 14, 2024 at 04:00 pm EDT
More quotes
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Calendar
2024-05-23
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
9.88
USD
Average target price
15.1
USD
Spread / Average Target
+52.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -54.09% | 363M | |
| -5.51% | 181B | |
| +2.33% | 112B | |
| -3.62% | 67.92B | |
| +1.52% | 50.1B | |
| +8.06% | 44.27B | |
| +9.39% | 40.41B | |
| +23.35% | 31.95B | |
| +0.67% | 25.82B | |
| +17.27% | 25.29B |
- Stock Market
- Equities
- NVRO Stock